CD274 and cancer: Immunotherapy with mAbs targeting cytotoxic T lymphocytes antigen 4 (CTLA-4), or the programmed cell death 1 (PD-1) and its ligand (PD-L1), have achieved impressive success in the treatment of different types of cancer [109].